IgA Nephropathy

Clin J Am Soc Nephrol. 2017 Apr 3;12(4):677-686. doi: 10.2215/CJN.07420716. Epub 2017 Feb 3.

Abstract

IgA nephropathy (IgAN) is a leading cause of CKD and renal failure. Recent international collaborative efforts have led to important discoveries that have improved our understanding of some of the key steps involved in the immunopathogenesis of IgAN. Furthermore, establishment of multicenter networks has contributed to rigorous design and execution of clinical trials that have provided important insights regarding immunotherapy in IgAN. In this article, we review emerging developments in clinical and translational IgAN research and describe how these novel findings will influence future strategies to improve the outcome of patients with IgAN.

Keywords: IGA; IgA nephropathy; chronic; corticosteroids; crescents; glomerulonephritis; humans; immunosuppression; immunotherapy; kidney; pathology; renal insufficiency; review; translational medical research.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Conservative Treatment
  • Drug Therapy, Combination
  • Glomerulonephritis, IGA / epidemiology
  • Glomerulonephritis, IGA / immunology*
  • Glomerulonephritis, IGA / pathology
  • Glomerulonephritis, IGA / therapy*
  • Hematuria / etiology
  • Humans
  • Immunologic Factors / therapeutic use
  • Mycophenolic Acid / therapeutic use
  • Phenotype
  • Proteinuria / etiology
  • Renal Insufficiency, Chronic / etiology
  • Rituximab / therapeutic use

Substances

  • Adrenal Cortex Hormones
  • Immunologic Factors
  • Rituximab
  • Mycophenolic Acid